ArticleOncology and therapy2024

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study.

Christian Schwabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.